-
An adult patient with fever and cough. This is something you probably see at least once a day and perhaps dozens of times a day in your ED during the flu season. But did you know about new recommendations that call for changes concerning when patients receive antibiotics, which diagnostic tests they are given, and whether they are discharged or admitted?
-
CryoCor (San Diego, California) said it has initiated its first U.S. multi-center pivotal clinical trial under a protocol approved by the FDA to treat atrial flutter with its CryoCor Cardiac Cryoablation System. CryoCors system is the first cryoablation device to be entered into a clinical pivotal trial in the U.S. for the treatment of atrial flutter, one of the leading causes of hospitalization due to rapid heart rhythm, the company said.
-
Franklin Beninsig has been appointed vice president of licensing and intellectual property for LifeWave (Sacramento, California). Beninsig has served as an intellectual property expert or litigation/ discovery coordinator for several law firms, including Fish & Richardson.
-
Advanced Cell Technology (ACT; Worcester, Massachusetts) reports that nuclear transfer cloning can be used to repair and regenerate the damage done to an infarcted heart.
-
MacroPore Biosurgery (San Diego, California) has received a fast-track Phase I/II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH; Bethesda, Maryland) to study the role of adipose-derived regenerative cells in treating myocardial infarction. This research will be conducted in collaboration with W. Robb MacLellan, MD, at the David Geffen School of Medicine at the University of California, Los Angeles.
-
Irelands first major effort in stem cell research is getting off the ground at the National University of Ireland (Galway). The National Center for Biomedical Engineering Science at the college has secured EUR 15 million from Science Foundation Ireland and another EUR 4 million from industry partners to establish the Regenerative Medicine Institute (REMEDI), which plans to develop approaches to treating vascular disease and arthritis based on genetically modifying adult stem cells.
-
The cytokine interleukin-6 plays an important role in triggering the rapid damage to heart muscle function that can develop in people with septic shock following infection with meningococci, a condition that often is fatal. The team making that discovery says it will be important to investigate IL-6 as a target for therapeutic agents.
-
Cardiovascular companies and cardiovascular topics captured much of the spotlight in healthcare investor conferences that took place last month a little more than a week apart at opposite ends of the country.
-
-
Michigan hospitals track bioterror; Ohio group issues surgical protocol; NFPA now allows hand-rub dispensers.
